Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
6992- Form,    Formononetin: pharmacological properties and therapeutic potential
- Review, Nor, NA
*BMD↑, *BioAv↑, *Half-Life↝, *BioAv↑,
6970- Form,    Formononetin, an isoflavone from Astragalus membranaceus inhibits proliferation and metastasis of ovarian cancer cells
- in-vitro, Ovarian, NA
tumCV↓, Apoptosis↑, Casp3↑, Casp9↑, Bax:Bcl2↑, TumCMig↓, TumCI↓, MMP2↓, MMP9↓, p‑ERK↓,
6997- Form,  PI,    Formononetin–piperine–phospholipid complex: enhancement of anti-osteoporotic activity and bioavailability in bone marrow in rats
- in-vivo, ostP, NA
*BMD↑, *BioAv↑,
6996- Form,  MET,    Formononetin and metformin act synergistically to inhibit growth of MCF-7 breast cancer cells in vitro
- in-vitro, BC, MCF7
TumCP↓, Apoptosis↑, Bcl-2↓, p‑ERK↓, eff↑,
6995- Form,    Formononetin inhibits neuroinflammation and increases estrogen receptor beta (ERβ) protein expression in BV2 microglia
- Review, Nor, BV2
*TNF-α↓, *IL6↓, *IL1β↓, *PGE2↓, *iNOS↓, *COX2/PTGS2↓, *neuroP↑, *Inflam↓,
6993- Form,  ISL,    Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell
- in-vitro, CRC, HCT116
AntiTum↑, TumCG↓, Apoptosis↑, Casp↑, Bcl-2↓, Bcl-xL↓,
6976- Form,    Study on the Mechanism of Formononetin Against Hepatocellular Carcinoma: Regulating Metabolic Pathways of Ferroptosis and Cell Cycle
- vitro+vivo, HCC, HepG2
ROS↑, DNAdam↑, TumCCA↑, CHK1↝, CDC25↝, CDK1↝, CycB/CCNB1↝, GSH↓, lipid-P↑, Ferroptosis↑, xCT/SLC7A11↓, P53↓, GPx4↓, other↝, TumCP↓, γH2AX↑, TumCG↓, Ki-67↓, PCNA↓, MMP↓,
6963- Form,    Formononetin-induced apoptosis by activation of Ras/p38 mitogen-activated protein kinase in estrogen receptor-positive human breast cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7 - in-vitro, BC, T47D
eff↝, TumCP↓, TumCP∅, MAPK↑, Bax:Bcl2↑, Apoptosis↑,
6964- Form,    Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo
- vitro+vivo, BC, MCF7
IGF-1↓, IGFR↓, PI3K↓, Akt↓, cycD1/CCND1↓, TumCP↓, TumCCA↑, TumCG↓, Dose↝,
6965- Form,    Formononetin inhibits colon carcinoma cell growth and invasion by microRNA‑149‑mediated EphB3 downregulation and inhibition of PI3K/AKT and STAT3 signaling pathways
- in-vitro, CRC, HCT116
TumCP↓, TumCI↓, cycD1/CCND1↓, TumCCA↑, MMP2↓, MMP9↓, miR-149↑, tumCV↓, p‑PI3K↓, p‑Akt↓, p‑STAT3↓,
6966- Form,    Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model
- NA, MM, NA
tumCV↓, Apoptosis↑, STAT3↓, STAT5↓, JAK1↓, JAK2↓, cSrc↓, ROS↑, Casp3↑, cl‑PARP↑,
6967- Form,  BTZ,    Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model
- in-vivo, Melanoma, U266 - in-vivo, Melanoma, RPMI-8226
eff↑, NF-kB↓, PI3K↓, Akt↓, AP-1↓, COX2/PTGS2↓, MMP9↓, Casp3↑, cl‑PARP↑, Dose↝, Ki-67↓, VEGF↓,
6968- Form,    Formononetin represses cervical tumorigenesis by interfering with the activation of PD-L1 through MYC and STAT3 downregulation
- in-vitro, Cerv, NA
PD-1↓, Myc↓, STAT3↓,
6969- Form,    Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer
- vitro+vivo, NSCLC, HCC827 - in-vitro, NSCLC, A549 - in-vitro, Lung, H1299
EGFR↓, Akt↓, GSK‐3β↑, TumCG↓, ChemoSen↑, Mcl-1↓, RadioS↑, tumCV↓, selectivity↑, Dose↝, Cyt‑c↑, BAX↑, Apoptosis↑, Ki-67↓, toxicity↓, chemoPv↑,
6977- Form,    Differential ability of formononetin to stimulate proliferation of endothelial cells and breast cancer cells via a feedback loop involving MicroRNA-375, RASD1, and ERα
- in-vitro, BC, MCF7 - in-vitro, BC, BT474 - in-vitro, BC, MDA-MB-231 - in-vitro, Nor, HUVECs
*Apoptosis↓, miR-375↝, p‑Akt↑, Bcl-2↑,
6971- Form,    In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa
- vitro+vivo, Cerv, HeLa
p‑Akt↓, Apoptosis↑, TumCG↓, Dose↝, PI3K↓, eff↑, ATP↓, OCR↓, TumCCA↑, IGF-1↓, angioG↓, TumCI↓,
6972- Form,  PacT,    Formononetin ameliorates the drug resistance of Taxol resistant triple negative breast cancer by inhibiting autophagy
- in-vivo, BC, MDA-MB-231
AntiCan↑, miR-199↓, ChemoSen↑, TumVol↓, Dose↝, TumCG↓, TumCCA↑, Apoptosis↑, TumAuto↓, eff↓,
6973- Form,    Formononetin enhances the chemosensitivity of triple negative breast cancer via BTB domain and CNC homolog 1-mediated mitophagy pathways
- Human, BC, NA
TumMeta↓, OS↑, TumCP↓, mtDam↑, Apoptosis↑, BACH1↑, eff↓, ChemoSen↑,
6974- Form,    Formononetin Defeats Multidrug-Resistant Cancers by Induction of Oxidative Stress and Suppression of P-Glycoprotein
- in-vitro, Cerv, HeLa
ROS↑, MMP↓, P-gp/ABCB1↓, ATPase↑, ChemoSen↑, eff↓,
6975- Form,    Formononetin inhibits colorectal cancer via the miR-490-3p/ABCC2 axis and synergizes with 5-fluorouracil: mechanistic insights and therapeutic implications
- vitro+vivo, CRC, NA
TumCP↓, MRP↓, miR-490↑, eff⇅, ChemoSen↑, ABCC2↓,
7010- Fuc,    Fucoidan enhances the effect of chemotherapeutic drug against drug-resistant lung cancer cells
- in-vitro, Lung, NA
ChemoSen↑, MMP9↓, Apoptosis↑, LC3s↓, Beclin-1/ATG6↓, β-catenin/ZEB1↓, TumCP↓, TumCMig↓, TumMeta↓,
7011- Fuc,  ATO,  VitA,RetA,    Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo
- NA, APL, APL NB4 - vitro+vivo, NA, NA
TumCCA↑, DNAdam↑, TumCP↓, Apoptosis↑, Diff↑, CD11b↑, eff↑, Dose↝,
7012- Fuc,    Fucoidan: A promising natural therapeutic agent for protecting human kidney health
- Review, EC, NA
*RenoP↑, *Inflam↓, *antiOx↑, *ROS↓, *BloodF↑, *diuretic↑, *BioAv↓, *BioAv↑, *MAPK↓, *ERK↑, *NLRP3↓, *NRF2↑, *MDA↓, *SOD↑, *GPx↑, *Catalase↑, *lipid-P↓, *DNAdam↓, *Fibrosis↓, *JAK2↓, *STAT3↓, *uricA↓, *COL1↓, *α-SMA↓, *SIRT1↑, *HO-1↑, *GLP-1R↑, *HMGB1↓, *RAGE↓, *NF-kB↓, *TGF-β1↓, *PI3K↓, *Akt↓, *GutMicro↑, *SCFAs↑, *Buty↑, *IBI↑, *TJ↑, *Dose↝,
7013- Fuc,    Fucoidan-based nanoparticles for colorectal cancer therapy: Mechanisms and preclinical insights
- Review, CRC, NA
*Inflam↓, *antiOx↑, AntiCan↑, BioAv↑, Apoptosis↑, angioG↓, Imm↝, ChemoSen↑, chemoP↑,
7014- Fuc,  5-FU,    Low-Molecular-Weight Fucoidan as Complementary Therapy of Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer
- in-vitro, CRC, HCT116 - in-vitro, Colon, Caco-2
tumCV↓, ChemoSen↑, TumCCA↑, cl‑PARP↑, KRAS↓, p‑ERK↓, PI3K↓, p‑Akt↓, TumCMig↓, MMP2↓, Dose↝,
7015- Fuc,    Effects of Ingesting Fucoidan Derived from Cladosiphon okamuranus Tokida on Human NK Cells: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Pilot Study
- Trial, Nor, NA
*NK cell↑, *toxicity↓,
7016- Fuc,    Therapies from Fucoidan: New Developments
- Review, Var, NA
*Bacteria↓, *BioAv↓, *Dose↝, *GutMicro↑, PD-1↝, ROS⇅, cl‑Casp↑, cl‑PARP↑, RadioS↑, *radioP↑, *neuroP↑, *Aβ↓,
7017- Fuc,    Comparative study on neuroprotective activities of fucoidans from Fucus vesiculosus and Undaria pinnatifida
- in-vitro, AD, PC12
*Apoptosis↓, *neuroP↑,
7026- Fuc,    Fucoidan
- Review, AD, NA
*Inflam↓, *ROS↓, *BioAv↓, *GutMicro↑, *neuroP↑, *glucose↝, *AntiThr↑, *chemoP↑, *Half-Life↝, *BBB∅, *AntiAge↑, Risk↑,
7018- Fuc,    Absorption Study of Mozuku Fucoidan in Japanese Volunteers
- Trial, Nor, NA
*Dose↝, *BioAv↝, *eff↝, *Inflam↓, *AntiThr↑, angioG↓, *AntiViral↑, *AntiTum↑, *antiOx↓, *BioAv↝,
7019- Fuc,    Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43
- vitro+vivo, HCC, HUH7
TumCI↓, p42↑, p44↑, MAPK↑, TumMeta↓, hepatoP↑, *antiOx↑, *TumCP↓, Vim↓, E-cadherin↓, Fibronectin↓, NDRG1↑, VMP-1↑, TumMeta↓,
7020- Fuc,    Systematic synthesis of low-molecular weight fucoidan derivatives and their effect on cancer cells
- in-vitro, BC, MCF7 - in-vitro, Cerv, HeLa - in-vitro, Nor, WI38
tumCV↓, selectivity↑, Apoptosis↑, Casp8↑, Casp9↑,
7025- Fuc,    Pilot clinical study to evaluate the anticoagulant activity of fucoidan
- Human, Nor, NA
*Dose↝, *BioAv↓, *antiCG↝,
7024- Fuc,    Fucoidan Alleviates Chemotherapy-Induced Peripheral Neuropathy via Activating the Gas6/MerTK Signaling Pathway to Reduce Neuroinflammation
NP/CIPN↓, Inflam↓,
7023- Fuc,    The Use of Oligo Fucoidan in Cancer Bearing Dogs Undergoing Chemotherapy: A Double-Blinded Study
- Trial, Var, NA
QoL∅, QoL↑,
7022- Fuc,    Antitumor Effects of Fucoidan on Human Colon Cancer Cells via Activation of Akt Signaling
- in-vitro, Colon, HT29
TumCG↓, TumCCA↑, Cyc↓, Akt↑, eff↓, Apoptosis↑, angioG↓,
7021- Fuc,    Fucoidan Prevents the Progression of Osteoarthritis in Rats
- in-vivo, Arthritis, NA
*Dose↝, *Cartilage↑, *TNF-α↓, *IL1β↓, *MMP1↓,
7001- Fuc,    Fucoidan reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent colorectal cancer
- Trial, CRC, NA
fatigue↓, eff↑, OS↑,
7000- Fuc,    Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial
- Trial, CRC, NA
DCR↑, OS∅, PFS∅, ORR∅, AEs∅, QoL∅,
7009- Fuc,    Effects of Fucoidan and Chemotherapeutic Agent Combinations on Malignant and Non-malignant Breast Cell Lines
- in-vitro, BC, MCF7 - in-vitro, Nor, MCF12A
selectivity↑, TumCCA↑, Casp3↑, Casp7↑, Casp9↑, ChemoSen↑, chemoP↑,
6998- Fuc,    Detection of Fucoidan in Urine after Oral Intake of Traditional Japanese Seaweed, Okinawa mozuku (Cladosiphon okamuranus Tokida)
- Human, Nor, NA
*BioAv↝,
6999- Fuc,    Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial
- Trial, HCC, NA
hepatoP↑, toxicity↓,
7002- Fuc,    The Auxiliary Effects of Low-Molecular-Weight Fucoidan in Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy Before Surgery: A Double-Blind, Randomized, Placebo-Controlled Study
- Trial, CRC, NA
fatigue↓, GutMicro↑,
7003- Fuc,  Chemo,    An Exploratory Study on the Anti-inflammatory Effects of Fucoidan in Relation to Quality of Life in Advanced Cancer Patients
IL1β↓, TNF-α↓, Inflam↓,
7004- Fuc,    Effectiveness of Fucoidan on Supplemental Therapy in Cancer Patients: A Systematic Review
- Review, Var, NA
OS↑, DCR↑, Inflam↓, fatigue↓,
7005- Fuc,    Fucoidan and cancer: a multifunctional molecule with anti-tumor potential
- Review, Var, NA
AntiCan↑, TumCCA↑, cycD1/CCND1↓, CDK4↓, MMP↓, Casp9↑, survivin↓, IAP1↓, Cyt‑c↑, Diablo↑, Bak↑, XIAP↓, VEGF↓, angioG↓, MMP2↓, MMP9↓, Akt↓, eff↝, TumMeta↓,
7006- Fuc,    Seaweeds in the Oncology Arena: Anti-Cancer Potential of Fucoidan as a Drug—A Review
- Review, Var, NA
*toxicity↓, *AntiViral↑, *antiOx↑, *Imm⇅, AntiCan↑, TumCCA↑, Apoptosis↑, TumMeta↓, angioG↓, antiNeop↑, VEGF↓, MMPs↓, BioAv↑, BioAv↑, ROS⇅, cl‑PARP↑, Casp3↑, Casp7↑, ROS↑, GSH↓, MMP↓, PI3K↓, ERK↓, MAPK↑, TumCP↓, Bax:Bcl2↑, TJ↑, ZO-1↑, OCLN↑, CLDN1↑, IBI↑, GutMicro↑, NK cell↑, STAT3↓, eff↑,
7007- Fuc,    The Therapeutic Potential of the Anticancer Activity of Fucoidan: Current Advances and Hurdles
- Review, Var, NA
TumCCA↑, Apoptosis↑, NK cell↑, chemoP↑, TumCG↓, *Inflam↓, *antiOx↑, *AntiThr↑, *AntiViral↑, angioG↓, ChemoSen↑, ROS↑, GSH↓, mtDam↓, MMP↓, DNMT3B↓, TumCG↓, Dose↝, Dose↝, QoL∅, fatigue∅, Dose↝,
7008- Fuc,    Ten Years of Research on Fucoidan and Cancer: Focus on Its Antiangiogenic and Antimetastatic Effects
- Review, Var, NA
antiOx↑, AntiViral↑, Imm↝, *AntiThr↑, *AntiDiabetic↑, AntiTum↑, TumMeta↑, angioG↓, Hif1a↓, VEGF↓, MMPs↓, EMT↓, N-cadherin↓, E-cadherin↑, TIMP1↑, PI3K↓, Akt↓, mTOR↓, MMP2↓, ChemoSen↑, OS↑, fatigue↓, CD31/PECAM-1↓,
948- Fuc,    Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia
- vitro+vivo, Bladder, T24/HTB-9 - in-vitro, Nor, HUVECs
p‑PI3k/Akt/mTOR↓, p‑p70S6↓, p‑4E-BP1↓, angioG↓, Hif1a↓, VEGF↑, TumCG↓, TumVol↓, TumW↓, Iron∅, ROS↓,

Showing Research Papers: 3951 to 4000 of 8269
Prev Page 80 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

ABCC2↓, 1,   AEs∅, 1,   DCR↑, 2,   miR-149↑, 1,   miR-199↓, 1,   miR-375↝, 1,   miR-490↑, 1,   ORR∅, 1,   PFS∅, 1,   VMP-1↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Ferroptosis↑, 1,   GPx4↓, 1,   GSH↓, 3,   Iron∅, 1,   lipid-P↑, 1,   ROS↓, 1,   ROS↑, 5,   ROS⇅, 2,   xCT/SLC7A11↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 1,   CDC25↝, 1,   MMP↓, 5,   mtDam↓, 1,   mtDam↑, 1,   OCR↓, 1,   p42↑, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

p‑PI3k/Akt/mTOR↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 5,   Akt↑, 1,   p‑Akt↓, 3,   p‑Akt↑, 1,   Apoptosis↑, 16,   Bak↑, 1,   BAX↑, 1,   Bax:Bcl2↑, 3,   Bcl-2↓, 2,   Bcl-2↑, 1,   Bcl-xL↓, 1,   Casp↑, 1,   cl‑Casp↑, 1,   Casp3↑, 5,   Casp7↑, 2,   Casp8↑, 1,   Casp9↑, 4,   Cyt‑c↑, 2,   Diablo↑, 1,   Ferroptosis↑, 1,   IAP1↓, 1,   MAPK↑, 3,   Mcl-1↓, 1,   Myc↓, 1,   survivin↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

cSrc↓, 1,   p‑p70S6↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,   tumCV↓, 6,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↓, 1,   LC3s↓, 1,   TumAuto↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

CHK1↝, 1,   DNAdam↑, 2,   DNMT3B↓, 1,   P53↓, 1,   cl‑PARP↑, 5,   PCNA↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↝, 1,   CDK4↓, 1,   Cyc↓, 1,   CycB/CCNB1↝, 1,   cycD1/CCND1↓, 3,   TumCCA↑, 12,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p‑4E-BP1↓, 1,   Diff↑, 1,   EMT↓, 1,   ERK↓, 1,   p‑ERK↓, 3,   GSK‐3β↑, 1,   IGF-1↓, 2,   IGFR↓, 1,   mTOR↓, 1,   PI3K↓, 6,   p‑PI3K↓, 1,   STAT3↓, 3,   p‑STAT3↓, 1,   STAT5↓, 1,   TumCG↓, 10,  

Migration(tgid=13) ⓘ

AP-1↓, 1,   ATPase↑, 1,   BACH1↑, 1,   CD11b↑, 1,   CD31/PECAM-1↓, 1,   CLDN1↑, 1,   E-cadherin↓, 1,   E-cadherin↑, 1,   Fibronectin↓, 1,   Ki-67↓, 3,   KRAS↓, 1,   MMP2↓, 5,   MMP9↓, 5,   MMPs↓, 2,   N-cadherin↓, 1,   p44↑, 1,   TIMP1↑, 1,   TJ↑, 1,   TumCI↓, 4,   TumCMig↓, 3,   TumCP↓, 10,   TumCP∅, 1,   TumMeta↓, 6,   TumMeta↑, 1,   Vim↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 9,   EGFR↓, 1,   Hif1a↓, 2,   VEGF↓, 4,   VEGF↑, 1,  

Barriers & Transport(tgid=15) ⓘ

IBI↑, 1,   MRP↓, 1,   OCLN↑, 1,   P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IL1β↓, 1,   Imm↝, 2,   Inflam↓, 3,   JAK1↓, 1,   JAK2↓, 1,   NF-kB↓, 1,   NK cell↑, 2,   PD-1↓, 1,   PD-1↝, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 3,   ChemoSen↑, 11,   Dose↝, 10,   eff↓, 4,   eff↑, 6,   eff⇅, 1,   eff↝, 2,   RadioS↑, 2,   selectivity↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   GutMicro↑, 2,   Ki-67↓, 3,   KRAS↓, 1,   Myc↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 4,   antiNeop↑, 1,   AntiTum↑, 2,   chemoP↑, 3,   chemoPv↑, 1,   fatigue↓, 4,   fatigue∅, 1,   hepatoP↑, 2,   NDRG1↑, 1,   NP/CIPN↓, 1,   OS↑, 4,   OS∅, 1,   QoL↑, 1,   QoL∅, 3,   Risk↑, 1,   toxicity↓, 2,   TumVol↓, 2,   TumW↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 1,  
Total Targets: 169

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

antiCG↝, 1,   Buty↑, 1,   diuretic↑, 1,   GLP-1R↑, 1,   SCFAs↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 5,   Catalase↑, 1,   GPx↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NRF2↑, 1,   ROS↓, 2,   SOD↑, 1,   uricA↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

glucose↝, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Apoptosis↓, 2,   iNOS↓, 1,   MAPK↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 4,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↑, 1,   PI3K↓, 1,   STAT3↓, 1,  

Migration(tgid=13) ⓘ

Cartilage↑, 1,   COL1↓, 1,   Fibrosis↓, 1,   MMP1↓, 1,   RAGE↓, 1,   TGF-β1↓, 1,   TJ↑, 1,   TumCP↓, 1,   α-SMA↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB∅, 1,   IBI↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   HMGB1↓, 1,   IL1β↓, 2,   IL6↓, 1,   Imm⇅, 1,   Inflam↓, 6,   JAK2↓, 1,   NF-kB↓, 1,   NK cell↑, 1,   PGE2↓, 1,   TNF-α↓, 2,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,   NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 4,   BioAv↝, 3,   Dose↝, 5,   eff↝, 1,   Half-Life↝, 2,  

Clinical Biomarkers(tgid=22) ⓘ

BloodF↑, 1,   BMD↑, 2,   GutMicro↑, 3,   IL6↓, 1,   RAGE↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   AntiDiabetic↑, 1,   AntiTum↑, 1,   chemoP↑, 1,   neuroP↑, 4,   radioP↑, 1,   RenoP↑, 1,   toxicity↓, 2,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 3,   Bacteria↓, 1,  
Total Targets: 72

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page